BACKGROUND: Treatments for muscle-invasive bladder cancer are multimodal, complex, and often carry significant risks of physical and psychological morbidity. The objectives of this study were to define the incidence and types of psychiatric illnesses diagnosed after treatment and to determine their impact on survival outcomes. METHODS: In total, 3709 patients who were diagnosed with clinical stage T2 through T4a bladder cancer from January 1, 2002, to December 31, 2011, from the Surveillance, Epidemiology, and End Results-Medicare were analyzed. Multivariable analysis and Cox proportional-hazards models were used to determine the predictors associated with psychiatric diagnosis and impact on survival outcomes. RESULTS: Of 3709 patients, 1870 (50.4%) were diagnosed with posttreatment psychiatric disorders. Patients who underwent radical cystectomy were identified as being at significantly greater risk of having a posttreatment psychiatric illness compared with those who received radiotherapy and/or chemotherapy (hazard ratio [HR], 1.19; 95% confidence interval [CI], 1.07-1.31; P 5.001). In adjusted analyses, diagnosis of a psychiatric disorder resulted in significantly worse overall survival (HR, 2.80; 95% CI, 2.47-3.17; P <.001) and cancer-specific survival (HR, 2.39; 95% CI, 2.05-2.78; P <.001). CONCLUSIONS: One-half of patients with muscle-invasive bladder cancer who underwent treatment were diagnosed with a psychiatric disorder, which resulted in worse survival outcomes compared with patients who did not have a posttreatment psychiatric diagnosis. This information can be used to inform interventions to educate patients with muscle-invasive bladder cancer regarding the impact of different treatments on mental health. Cancer
INTRODUCTION
There will be an estimated 79,030 new cases and 16,870 deaths from bladder cancer in the United States in 2017. 1 Despite the multimodality treatment paradigm for muscle-invasive bladder cancer (MIBC), patients have estimated 5-year survival rates ranging from 26% to 64%. 2, 3 Moreover, the morbidity and mortality of associated treatments for MIBC are nonnegligible. 4 Taking this into account, survival outcomes have remained unaltered over the last 3 decades. 5 Cancer diagnosis and treatment carry significant physical and emotional stress, which may affect survival outcomes. Patients with cancer are at increased risk for psychiatric disorders from the prediagnostic to the posttreatment period, because it has been demonstrated that approximately one-third of patients with cancer are at risk of developing a psychiatric disorder. 6, 7 Disorders like depression cause serious suffering and distress, reduced adherence to cancer care, and increased risk of hospital readmission, which, in turn, may lead to worse survival. [7] [8] [9] Different cancers present with various degrees and types of psychiatric disorder risks. Patients diagnosed with lung cancer are more likely to be diagnosed with depression or anxiety disorders than those diagnosed with prostate cancer. 10, 11 Moreover, although studies that investigate posttreatment psychiatric disorders for any type of cancer are lacking, 1 recent meta-analysis indicated that the receipt of high-dose chemotherapy (CTX) was associated with an increased risk of cognitive dysfunction among patients with breast cancer. 12 It has been reported that, compared with the general population, patients who have bladder cancer are at higher risk of suicide, with the highest risk of suicide in the first 5 years after diagnosis. 13 In addition, patients undergoing radical cystectomy (RC) for MIBC were at even greater risk for suicide than those who received no intervention. 14 Despite this knowledge, there are limited data regarding the incidence and types of psychiatric disorders after treatment for MIBC. Moreover, the impact of having a posttreatment psychiatric disorder on survival outcomes among patients with MIBC remains to be determined. Against this backdrop, we sought to investigate the incidence of posttreatment psychiatric diagnoses after undergoing RC or receiving radiotherapy (RTX) and/or CTX. We hypothesized that having a posttreatment psychiatric diagnosis would be associated with worse survival outcomes in patients with MIBC compared with those who did not have a posttreatment psychiatric diagnosis.
MATERIALS AND METHODS

Data Source
We used Surveillance, Epidemiology, and End Results (SEER)-Medicare-linked data from the National Cancer Institute. SEER collects data on new cancer cases from 18 locations and sources in the United States in the most recent release, which allows the results to be generalized to the US population. Cancer cases reported in the SEER database conformed to the standards of the North American Association of Central Cancer Registries, and case ascertainment in the SEER data was 98% complete. 15 The SEER database reports data on patient tumor characteristics (including stage, grade, and histology), demographics, and follow-up information. The Medicare database comprises data on inpatient and outpatient claims. The Institutional Review Board of The University of Texas Medical Branch regarded this study exempt from any obligation or liabilities.
Ascertainment of the Study Cohort
Our analysis was restricted to elderly (age 66 years) patients who were diagnosed with stage II, III, and IV transitional cell or urothelial carcinoma from January 1, 2002, to December 31, 2011, for whom claims data were available up to December 31, 2013 . Because patients who do not receive treatment for bladder cancer may differ significantly from those who do receive treatment, the study was restricted to patients who had received treatment for bladder cancer and did not have a psychiatric diagnosis within 12 months before receipt of treatment. 16 Only patients who had Medicare fee-forservice coverage and for whom Medicare Parts A and B claims data were available were included in the study. Patients with any other nonbladder cancer diagnosis were excluded. The final cohort consisted of 3709 patients (Supporting Fig. 1 ).
Identification of Bladder Cancer Treatments
Patients who underwent RC were identified using procedure codes, including both open and robot-assisted laparoscopic surgery with or without pelvic lymph node dissection. Patients who received RXT were classified based on the Medicare diagnosis and procedure codes consistent with radiotherapeutic procedures. Patients who received CTX were identified using Healthcare Procedure Common Procedure Coding System codes consistent with chemotherapeutic agents that are commonly used to manage bladder cancer in the absence of a concomitant code for RC. The RC group included patients who underwent surgery alone or in combination with RXT or CXT. 17 Those who received either CXT alone, or RXT alone, or both CXT and RXT were placed in 1 group, because bladder-sparing protocols for invasive bladder cancer often combine the use of CXT and RXT.
Identification of Psychiatric Illnesses
All patients were followed for 1 year after the date they started treatment for bladder cancer to determine psychiatric illnesses. Patients who underwent RC were followed after they were discharged from the hospital. Psychiatric illnesses were identified using International Statistical Classification of Diseases-Ninth Edition codes, excluding developmental psychiatric diagnoses and organic mental disorders (Supporting Table 1 ). Patients who had any International Statistical Classification of Diseases-Ninth Edition code for a psychiatric illness after their treatment start date up to 1 year were classified as having a posttreatment psychiatric illness. Each treatment group (RC, RTX and/or CTX) was stratified into 2 subgroups: those with and without a posttreatment psychiatric diagnosis. Patients who had a posttreatment psychiatric diagnosis were further stratified to discern the incidence of each psychiatric diagnosis type that we identified. Psychiatric diagnosis types were obtained from the International Statistical Classification of Diseases and Related Health Problems-World Health Organization Version for Cancer 2016. 18 Supporting Table 1 includes a list of all specific psychiatric diagnoses that fell under each psychiatric diagnosis type we identified in the current study.
Survival Outcome
Patients were followed for 1 year to determine all-cause and cancer-specific survival. Cancer-specific survival was defined as death from cancer. Overall survival and cancerspecific survival were first determined for all patients who had a psychiatric disorder(s) and compared with those who did not have a posttreatment psychiatric diagnosis. Patients with posttreatment psychiatric disorders were then stratified based on the number of psychiatric diagnoses they received during the posttreatment period (1 year), and overall and cancer-specific survival were then investigated. The SEER cancer registry uses algorithms to process causes of death from death certificates to identify a single, disease-specific, underlying cause of death. To accurately classify the cause of death, SEER takes into account causes of death in conjunction with tumor sequence (ie, only 1 tumor or the first of subsequent tumors), the site of the original cancer diagnosis, and comorbidities (eg, acquired immunodeficiency syndrome and/or site-related diseases).
Study Covariates
By using the SEER-Medicare database, we extracted information on patient age, sex, race/ethnicity (non-Hispanic white, non-Hispanic black, Hispanic, and non-Hispanic other races), marital status (single, married, and unknown), and SEER region (Northeast, South, Midwest, and West). We determined socioeconomic characteristics for patients from SEER-Medicare. County-level education was defined according to the percentage of residents with at least 4 years of college education. County-level median household income was acquired through linkage to the area health resource file and then divided into quartiles. Comorbidity was assessed using the Klabunde modification of the Charlson index during the year before cancer diagnosis. 19 The Klabunde modification uses comorbid conditions identified by the Charlson comorbidity index and incorporates the diagnostic and procedure data contained in hospital claims and physician/outpatient claims. Diagnosing providers were identified through the American Medical Association Physician Masterfile linked with outpatient claims.
Statistical Analysis
We conducted univariate analyses to assess the association between bladder cancer treatments (RC, RTX and/or CTX) and the covariates described above using the Pearson chi-square test. Unadjusted cumulative incidence curves were generated to compare the incidence of posttreatment psychiatric disorders for each treatment modality. To investigate factors related to posttreatment psychiatric diagnosis among patients newly diagnosed with stage II, III, or IV bladder cancer, we performed a Fine and Gray competing-risk hazards regression model while treating death as a competing risk. The model included the following independent variables: bladder cancer treatment, year of diagnosis, age, sex, race/ethnicity, marital status, income, education, county population, census region, disease grade, and comorbidity.
To determine the association of psychiatric illnesses with all-cause survival, time-dependent Cox proportional hazards regression was used, and the Fine and Gray competing-risk hazards regression model was used for cancer-specific survival; deaths from noncancer causes were treated as a competing risk. Psychiatric illness was assessed using cumulative effects and was modeled as a time-varying variable in both regression models; and all other covariates, such as patient demographics and clinical characteristics, were modeled as fixed variables. Modeling of psychiatric illness as a time-varying variable in time-dependent Cox regression models is a better alternative to the traditional landmark analysis approach. 20 Statistical significance was defined as P < .05. All statistical tests were 2-sided, and all analyses were done using the SAS statistical software package (version 9.4; SAS Institute Inc, Cary, NC).
RESULTS
Patient demographics according to treatment type are summarized in Table 1 . Of the patients who received treatment, 1861 (50.2%) underwent RC, and 1848 (49.8%) received RTX and/or CTX. Patients who underwent surgery were younger, married, more educated, had fewer comorbidities, and had less advanced stage disease than those who received RTX and/or CTX. Of those patients who underwent RC, 225 (12.1%) and 374 (20.1%) received neoadjuvant and adjuvant CTX, respectively (P < .001).
Overall 998 patients (53.6%) who underwent RC developed posttreatment psychiatric disorder(s) compared with 872 patients (47.2%) who received RTX and/or CTX (P < .001) ( Table 2 ). Among those who underwent RC, the most common psychiatric disorder types were mental and behavioral disorders caused by psychoactive substance use (19.0%), depressive episodes (13.5%), and symptoms and signs involving cognitive functions and awareness (13.1%); whereas the most common psychiatric disorder types in those who received RTX and/or CTX, in order of incidence, were mental and behavioral disorders caused by psychoactive substance use (13.7%), symptoms and signs involving cognitive functions and awareness (13.5%), dizziness and giddiness (11.9%), followed by depression (9.2%). Of the 1132 patients (30.5%) who had identifying provider information available, the most common type of diagnosing provider included internal medicine (18.1%), family medicine (8.5%), emergency medicine (8.0%), urology (6.8%), psychiatry (3.9%) and hematology/oncology (3.5%).
Multivariable results from the competing-risks regression model discerning predictors for psychiatric diagnosis are listed in Table 3 . Patients who underwent surgery were significantly more likely to be diagnosed with a posttreatment psychiatric disorder than those who received RTX and/or CTX (hazard ratio [HR] 1.19; 95% Table 2 ). Adjusted analyses for overall and cancer-specific survival also were performed (Table 4) . Diagnosis of a psychiatric disorder resulted in significantly worse overall survival (HR, 2.80; 95% CI, 2.47-3.17; P < .001) and cancer-specific survival (HR, 2.39; 95% CI, 2.05-2.78; P < .001) (Fig. 1 ). Increasing number of psychiatric diagnoses was associated with worse overall survival (3 vs none: HR, 2.21; 95% CI, 1.85-2.66; P < .001) and cancer-specific survival (3 vs none: HR, 2.14; 95% CI, 1.73-2.65; P < .001). The median time to overall or cancer-specific survival according to psychiatric diagnosis was not reached.
DISCUSSION
The National Comprehensive Cancer Network survivorship guidelines recommend the assessment of late psychological and physical effects as well as intervention for the consequences of cancer and its treatment (including psychological distress and financial and social concerns). 21 The American Society of Clinical Oncology recommends routine screening, follow-up, and reassessment of psychological distress to improve the quality of life for patients with cancer and potentially to improve survival. 22 A meta-analysis indicated that psychosocial interventions may alleviate pain in patients with cancer, 23 and others reported that minimal resources are needed to improve quality of life through psychological interventions in such patients. 24 Communication between caregivers and patients is imperative to improve the efficiency of screening and timely intervention for psychosocial distress in patients with cancer. Treatment for bladder cancer is multimodal, complex, and carries a significant risk of morbidity. In the current study, the diagnosis and treatment of bladder cancer carried a significant psychological burden, and up to one-half of patients had a post-treatment psychiatric diagnosis. Moreover, patients who developed psychiatric disorders after receiving any type of treatment had worse overall and cancer-specific survival.
Our study has several important findings. First, we observed that one-half of patients who underwent any type of treatment had a posttreatment psychiatric disorder. Although prior research illustrated an increase in suicidal risk for patients undergoing RC versus those who did not undergo any treatment, 14 no study to date has assessed the incidence of the full spectrum of psychiatric disorders after treatment for MIBC. The incidence of developing posttreatment psychiatric disorders was significantly greater for patients who underwent surgery than for those who received RTX and/or CTX. An investigation into the types of psychiatric disorders revealed that there is a tendency for patients to develop a mental and behavioral disorder because of psychoactive substance use. 25, 26 Patients who underwent surgery had a markedly greater risk for the development of depressive disorders and were at increased risk of a first depressive episode than those who received RTX and/or CTX. Prior studies in other cancers have noted a similar increased risk of depression after cancer treatment. 16, 27 This increased risk of depression after surgery may be attributed to not only the physical and mental demands of undergoing surgical treatment but also to the lack of proper screening and counseling before depression onset. 27 Moreover, the necessity for urinary diversion (orthotopic, continent, or incontinent [ie, ileal conduit]) may further increase the risk of psychiatric disorders compared with other bladdersparing treatment options. It is noteworthy that patients who underwent RC who and received adjuvant (and not neoadjuvant) CTX were less likely to be diagnosed with a posttreatment psychiatric disorder. The impact of CTX on cognitive function is well documented; some studies have illustrated a dose effect, with higher doses reported to have a greater impact on mental health in other malignancies. 28, 29 However, the timing of CTX receipt and mental illness among patients with cancer remains to be determined. Given the limited numbers of patients who underwent RC and received CTX in the current study, our findings warrant further investigation on the impact of type, dose, duration, and timing of CTX among these patients. Second, we identified several predictors for a posttreatment psychiatric disorder. Older, married patients were less likely to be diagnosed with a posttreatment psychiatric disorder. Given the morbidity and mortality associated with MIBC despite treatment (approximately 50% at 5 years), it may be argued that the relatively young age and likelihood of being diagnosed with a posttreatment psychiatric disorder could be attributed to inherent selection bias. Marital status has previously been associated with survival outcomes in patients undergoing cancerdirected surgery, 30 with worse overall and cancer-specific survival outcomes among single, divorced, or widowed patients. 30, 31 Rationale for these findings include an improved social network among married patients, with additional reinforcement of health and improved quality of life. 30 Furthermore, as supported by the current results, married patients are less likely to be depressed, which may contribute to improved survival outcomes. 32 Patient support groups and survivorship programs are an essential component of cancer care, and our current data support the effectiveness of these programs, especially among unmarried patients. 31 Third, patients who had more advanced stage disease were significantly more likely to be diagnosed with a posttreatment psychiatric disorder. Cancer survivors are at significant risk for psychiatric illness after diagnosis and according to treatment type. 33 Patients with more aggressive disease features are more likely to undergo multiple treatments, which may carry significant physical and emotional burden to the patient. 12 Our findings support a recent study indicating that patients who had localized cancer were at significantly increased risk for mental disorders after diagnosis. 34 Like in other cancer types, patients who have bladder cancer face a worse prognosis with more advanced stage of disease. 4, 35 The combined burden of cancer diagnosis and prognosis with multiple treatment options places these patients at greater risk for mental disorders, which adversely impact their health patients. 36 Patients with higher stage and localized disease represent an at-risk cancer population for mental disorders that warrants targeted preventative and intervention programs. 21 Fourth, we observed that a more recent year of treatment was associated with an increased likelihood of having a posttreatment psychiatric diagnosis. Diagnosis and treatment of mental disorders are well recognized and have become more commonplace in recent years. 16, 21 Moreover, implementation of effective mental disorder screening programs, including those for depression, have likely increased the diagnosis of mental disorders in more recent years. 6, 21 Nonetheless, increased screening, diagnosis, and treatment of mental disorders among patients with cancer are needed. Heterogeneity in specialty of the diagnosing provider highlights a need for further awareness across all disciplines regarding the impact of psychiatric illness among patients with cancer, as observed in the current study. Failure to address the psychosocial needs of patients who have cancer can compromise the effectiveness of health care and thereby adversely affect their health and survival. 36 Fifth, we observed that patients who developed posttreatment psychiatric disorders had significantly worse overall and cancer-specific survival outcomes. Moreover, we observed a dose-response relation, with increased numbers of psychiatric diagnoses associated with worse overall and cancer-specific survival. These findings suggest the important interplay between psychiatric illness and survival outcomes after treatment for MIBC. 13, 14 Although oncologic outcomes and perioperative management are critically important to ameliorate the morbidity and mortality associated with surgery, we provide evidence to suggest the importance of addressing the nononcologic psychosocial needs of these patients as well. Why patients who develop posttreatment psychiatric disorders have poorer survival outcomes is somewhat speculative. Previous studies from the breast cancer literature have reported that patients who have mental illness do not receive guideline-consistent treatment and follow-up, resulting in an increased risk of cancer-specific mortality compared with patients who do not have mental illness. 37, 38 If such disparities exist for patients with bladder cancer and posttreatment psychiatric disorders, then additional measures to improve care and outcomes for these patients are required. These may include incorporating improved screening methods for psychiatric disorders like depression, the use of social workers to assist with maintaining follow-up appointments, and the implementation of survivorship clinics dedicated to assessing the nononcologic needs of patients with cancer.
Although our findings are relevant for policy and clinical decision making, they must be interpreted within the context of the study design. First, the patients identified in the current study were older, and we cannot comment on the incidence of posttreatment psychiatric disorders among younger patients with bladder cancer. However, most patients diagnosed with bladder cancer for the first time before undergoing a treatment are in the sixth decade of life, and we provide a contemporary analysis of posttreatment psychiatric disorders among patients with bladder cancer who were undergoing treatment. Second, mental disorders represent a chronic disease state Cancer characterized by remitting and recurring episodes, which may have an antecedent presence in a significant portion of the population. Although we excluded patients who had a psychiatric diagnosis the year before treatment, we cannot account for potential confounding of our results because of patients who had with a mental illness greater than 1 year prior. Third, our analysis is retrospective and included psychiatric diagnoses derived from administrative claims data, which have inherent limitations. Prior studies determined that the accuracy of using claims data to conduct research involving psychiatric diagnoses has positive and negative predictive values of 80% to 90% and >90%, respectively. 39, 40 This supports the use of these data to provide a generalizable, population-based assessment of posttreatment psychiatric illness and its impact on survival outcomes. Fourth, we controlled for area-level socioeconomic (income and education) factors, which limited an individual-level assessment. Fifth, treatment types included patients who received RXT with or without CTX, and this may include a large proportion of patients who receive palliative treatment. Finally, the use of large amounts of population-based data to identify patients with psychiatric disorders and whether these diagnoses derived from administrative claims account for clinically relevant psychiatric conditions remains to be determined. 41 
Conclusions
In the current study, 50.4% of patients had at least 1 psychiatric diagnosis after treatment for MIBC. Diagnosis of a posttreatment psychiatric disorder was associated with worse overall and cancer-specific survival, thus underscoring the importance of addressing posttreatment psychiatric disorders, which may improve survival in these patients. To optimize survival, nononcologic interventions like depression screening and survivorship clinics are critical. This information can be used to inform interventions to educate patients who have MIBC regarding the impact of different treatments on mental health.
